Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 9;11(2):16.
doi: 10.1038/s41408-021-00420-8.

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Valentín Garcia-Gutiérrez  1 , Alejandro Luna  2 , Juan M Alonso-Dominguez  3 , Natalia Estrada  4 , Concepcion Boque  5 , Blanca Xicoy  4 , Pilar Giraldo  6 , Anna Angona  7 , Alberto Alvarez-Larrán  8 , Fermin Sanchez-Guijo  9 , María José Ramírez  10 , Elvira Mora  11 , Patricia Vélez  12 , Ana Rosell  13 , Mercedes Colorado Araujo  14 , Beatriz Cuevas  15 , Miguel Sagüés  4 , Montserrat Cortes  16 , Manuel Perez Encinas  17 , Luis Felipe Casado Montero  18 , Melania Moreno Vega  19 , Luis Serrano  20 , Valle Gomez  21 , Carmen Garcia-Hernandez  22 , Sunil Lakhwani  23 , Antonio Paz Coll  24 , Raquel de Paz  25 , Sara Suarez-Varela  26 , Andrés Fernandez-Ruiz  4 , Raul Perez Lopez  27 , Almudena Ortiz-Fernández  28 , Antonio Jiménez-Velasco  29 , Juan Luis Steegmann-Olmedillas  21 , Juan Carlos Hernández-Boluda  30
Affiliations

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Valentín Garcia-Gutiérrez et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

V.G.G.: Novartis, Incyte, Pfizer and BMS - Speaker Honoraria, advisory committees and research funding; J.M.A.D.: Research funding from Incyte, Celgene, Pfizer, Astellas. BMS - Speaker Honoraria, advisory committees; Pfizer - Speaker Honoraria, advisory committees. Incyte - Advisory committees; J.L.S.: Novartis - Consultancy, Speaker Honoraria, advisory committees; research grants; BMS - Consultancy, Speaker Honoraria, advisory committees; research grants; Pfizer - Consultancy, Speaker Honoraria, advisory committees; research grants: Incyte - Advisory committees. S.L.L.: Novartis - Speaker honoraria, advisory committees; BMS - Speaker honoraria. The rest of the authors declare that they have no conflict of interest.

References

    1. García-Gutiérrez V, Hernández-Boluda JC. Current treatment options for chronic myeloid leukemia patients failing second-generation tyrosine kinase inhibitors. J. Clin. Med. 2020;9:2251. doi: 10.3390/jcm9072251. - DOI - PMC - PubMed
    1. Ibrahim A, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116:5497–5500. doi: 10.1182/blood-2010-06-291922. - DOI - PMC - PubMed
    1. Hochhaus A, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 2017;376:917–927. doi: 10.1056/NEJMoa1609324. - DOI - PMC - PubMed
    1. García-Gutiérrez V, Hernández-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603. doi: 10.3389/fonc.2019.00603. - DOI - PMC - PubMed
    1. Hochhaus A, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125–2137. doi: 10.1038/s41375-020-0915-9. - DOI - PMC - PubMed

LinkOut - more resources